The Fab’entech biopharmaceutical company Fab’entech is launching the production of its treatment against Ebola.

Fab’entech, specialising in the treatment of emerging infectious diseases for 5 years, is offering passive anti-infective immunotherapy solutions based on specific and highly-purified polyclonal antibodies.